Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck

Published:2024-01-01 Issue:1 Volume:10 Page:142
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Parast Layla¹,Tian Lu²,Wei Lee-Jen³

Affiliation:

1. Department of Statistics and Data Sciences, University of Texas at Austin

2. Department of Biomedical Data Science, Stanford University, Stanford, California

3. Department of Biostatistics, Harvard T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2812298/jamaoncology_parast_2023_le_230031_1704491803.60693.pdf

Reference5 articles.

1. Efficacy and safety of nivolumab plus ipilimumab vs nivolumab alone for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck: the phase 2 CheckMate 714 randomized clinical trial.;Harrington;JAMA Oncol,2023

2. Evaluating treatment effect based on duration of response for a comparative oncology study.;Huang;JAMA Oncol,2018

3. Analysis of response data for assessing treatment effects in comparative clinical studies.;Huang;Ann Intern Med,2020

4. Appropriate analysis of duration of response data in cancer trials.;McCaw;JAMA Oncol,2020

5. Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio.;Pak;JAMA Oncol,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP